Cargando…

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer for which there is no effective treatment. Previously, we and others demonstrated that CXCR4 surface expression is an independent prognostic factor for disease relapse and survival in breast cancer. In this study, we investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Sixian, Peng, Xun, Li, Xiaoli, Yang, Ping, Xie, Linhao, Li, Yaochen, Du, Caiwen, Zhang, Guojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359214/ https://www.ncbi.nlm.nih.gov/pubmed/25544759

Ejemplares similares

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer
por: Wang, Yuyi, et al.
Publicado: (2018)

Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells
por: Yang, Meng, et al.
Publicado: (2019)

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells
por: Zhang, Yang, et al.
Publicado: (2018)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Silencing CTNND1 Mediates Triple-Negative Breast Cancer Bone Metastasis via Upregulating CXCR4/CXCL12 Axis and Neutrophils Infiltration in Bone
por: Lin, Qun, et al.
Publicado: (2021)

Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells
por: Chen, Lian, et al.
Publicado: (2016)

EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas
por: Li, Rong-Hui, et al.
Publicado: (2017)

Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity
por: Heijink, Anne Margriet, et al.
Publicado: (2019)

Urtica dioica Leaf Infusion Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Cisplatin Treatment
por: Nafeh, Guy, et al.
Publicado: (2023)

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
por: Li, Weijia, et al.
Publicado: (2023)

Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A
por: vel Szic, Katarzyna Szarc, et al.
Publicado: (2017)

Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC)
por: Chuan, Tian, et al.
Publicado: (2020)

Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells
por: Li, Shujun, et al.
Publicado: (2020)

Chitosan nanoparticle-delivered siRNA reduces CXCR4 expression and sensitizes breast cancer cells to cisplatin
por: Yu, Shaonan, et al.
Publicado: (2017)

Triple-Negative Breast Cancer Cells Recruit Neutrophils by Secreting TGF-β and CXCR2 Ligands
por: SenGupta, Shuvasree, et al.
Publicado: (2021)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
por: Lefort, S, et al.
Publicado: (2017)

The CXCR4-Dependent LASP1-Ago2 Interaction in Triple-Negative Breast Cancer
por: Tilley, Augustus M. C., et al.
Publicado: (2020)

Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells
por: Wen, Yuqing, et al.
Publicado: (2019)

Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
por: Balza, Enrica, et al.
Publicado: (2021)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells
por: Zhao, Zhijing, et al.
Publicado: (2018)

HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy
por: Mehta, Meghna, et al.
Publicado: (2016)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Sun, Shanshan, et al.
Publicado: (2021)

Role of the CXCR4-LASP1 Axis in the Stabilization of Snail1 in Triple-Negative Breast Cancer
por: Subramaniyan, Boopathi, et al.
Publicado: (2020)

Saikosaponin A Inhibits Triple-Negative Breast Cancer Growth and Metastasis Through Downregulation of CXCR4
por: Wang, Ying, et al.
Publicado: (2020)

CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
por: Ghallab, Alaa M., et al.
Publicado: (2022)

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft
por: Bharti, Santosh K., et al.
Publicado: (2018)

Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT
por: Jin, Yujin, et al.
Publicado: (2019)

Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression
por: Xu, Pengfei, et al.
Publicado: (2021)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

miR-638 mediated regulation of BRCA1affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer
por: Tan, Xiaohui, et al.
Publicado: (2014)

Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer
por: Umeh-Garcia, Maxine, et al.
Publicado: (2022)

Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial–mesenchymal transition in triple‐negative breast cancer
por: Lv, Zhi‐Dong, et al.
Publicado: (2016)

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment
por: Misra, Shrilekha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fvba8u7v44t14e9vovfffdi9kk